OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Shadman on the Investigation of Sonrotoclax Combination Therapy in Treatment-Naive CLL

August 12th 2024

Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia.

Dr Ducreux on Findings From the TRANSMET Trial in Colorectal Liver Metastases

August 12th 2024

Michel Ducreux, MD, PhD, discusses findings from the TRANSMET trial of chemotherapy plus liver transplantation in unresectable colorectal liver metastases.

Dr El-Jawahri on the Impact of Palliative Care on End-of-Life Care for AML and MDS

August 12th 2024

Areej El-Jawahri, MD, discusses a trial investigating a palliative oncology care model for patients with AML and MDS receiving nonintensive therapy.

Dr Aggarwal on the Rationale For Evaluating CAN-2409 in NSCLC

August 12th 2024

Charu Aggarwal, MD, MPH, FASCO, discusses the evaluation of CAN-2409, valacyclovir, and continued immune checkpoint inhibitors in NSCLC.

Dr Krishnan on the Evolving Role of Belantamab Mafodotin in Multiple Myeloma

August 12th 2024

Amrita Krishnan, MD, discusses the evolving role of belantamab mafodotin in the treatment of multiple myeloma.

Dr Mukhtar on Recurrence Risk in Invasive Lobular Carcinoma

August 9th 2024

Rita Mukhtar, MD, discusses the risk of disease recurrence in patients with invasive lobular carcinoma.

Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA Mutations

August 9th 2024

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

Dr Steiner on a Microdevice for Evaluating Responses to RCC Treatment

August 9th 2024

Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.

Dr Machaalani on the Interaction Between c-Met and AXL in RCC

August 9th 2024

Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.

Dr Lynce on Ongoing Trials Evaluating Novel Combinations in Inflammatory Breast Cancer

August 9th 2024

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Dr Leidner on the Multivalent Vaccine DPV-001 in Advanced or Metastatic HNSCC

August 8th 2024

Rom S. Leidner, MD, discusses data for DPV-001 combined with PD-1inhibition with or without a GITR agonist in advanced or metastatic HNSCC.

Dr Bazhenova on Updated Data From the TRUST-I Trial of Taletrectinib in ROS1+ NSCLC

August 8th 2024

Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Dr Westin on the FDA Approval of Durvalumab Plus Chemo in dMMR Endometrial Cancer

August 8th 2024

Shannon Westin, MD, MPH, FACOG, discusses the FDA approval of durvalumab plus chemotherapy in dMMR advanced or recurrent endometrial cancer.

Dr Perez on the Efficacy and Safety of Frontline Petosemtamab Plus Pembrolizumab in HNSCC

August 8th 2024

Cesar A. Perez, MD, discusses the ongoing investigation of frontline petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma.

Dr Bekaii-Saab on the Final Analysis of MOUNTAINEER in HER2+ CRC

August 8th 2024

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

Dr Friedlander on the Duravelo-2 Trial for Advanced or Metastatic Urothelial Cancer

August 8th 2024

Terence W. Friedlander, MD, discusses the investigation of BT8009 in the Duravelo-2 study in patients with advanced or metastatic urothelial cancer.

Dr Linscott on Future Directions for utDNA Research in Bladder Cancer

August 8th 2024

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

August 8th 2024

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Dr Shallis on the Utility of Luspatercept in the ELEMENT-MDS Trial in MDS

August 8th 2024

Rory Shallis, MD, discusses the utility of luspatercept in the context of the phase 3 ELEMENT-MDS trial for patients with myelodysplastic syndrome.

Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC

August 7th 2024

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.